Explore

Trendline Trendline
Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success

Citius Oncology Reports Q2 2026 Financial Results Highlighting LYMPHIR Launch Success
Trendline Trendline
Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch

Citius Oncology Secures $36.5 Million Financing Amid Strong LYMPHIR Launch
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment with PIKTOR Amid Financial Growth
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal
Trendline Trendline
Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026

Citius Oncology Reports Strong Financial Growth and Strategic Developments in Q2 2026
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress

Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress

Guided Therapeutics Reports Q1 2026 Financial Results Amid Regulatory Progress
Trendline Trendline
Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026

Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026

Guided Therapeutics Inc Reports No Revenue and Increased Net Loss in Q1 2026
Trendline Trendline
Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion

Legend Biotech Reports Strong Q1 2026 Growth Driven by CARVYKTI Expansion
Trendline Trendline
Personalis to Engage with Investors at Upcoming Conferences

Personalis to Engage with Investors at Upcoming Conferences

Personalis to Engage with Investors at Upcoming Conferences
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026

Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026